Compare Bioavailability of RO7239361 After Subcutaneous Injection

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

October 17, 2017

Study Completion Date

October 17, 2017

Conditions

Healthy

Interventions

DRUG

RO7239361

Specified dose on specified days

Trial Locations (1)

WCCT Global, Inc., Cypress

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT03100630 - Compare Bioavailability of RO7239361 After Subcutaneous Injection | Biotech Hunter | Biotech Hunter